Form 8-K - Current report:
SEC Accession No. 0001193125-22-301064
Filing Date
2022-12-08
Accepted
2022-12-08 16:31:10
Documents
12
Period of Report
2022-12-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d425106d8k.htm   iXBRL 8-K 31579
  Complete submission text file 0001193125-22-301064.txt   155645

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20221202.xsd EX-101.SCH 2529
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20221202_lab.xml EX-101.LAB 17971
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20221202_pre.xml EX-101.PRE 11247
6 EXTRACTED XBRL INSTANCE DOCUMENT d425106d8k_htm.xml XML 3513
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 221452899
SIC: 2834 Pharmaceutical Preparations